Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q41429394

about

Current clinical immunotherapeutic approaches for head and neck cancer CAR models: next-generation CAR modifications for enhanced T-cell function From kinetics and cellular cooperations to cancer immunotherapies Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy CAR T Cell Therapy: A Game Changer in Cancer Treatment High-content molecular profiling of T-cell therapy in oncology Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia Immunotherapy in hematologic malignancies: past, present, and future.Analysis of Risk Factors of Peripherally Inserted Central Catheter Induced Catheter-related Infection in Patients with Leukemia.Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.Engineering cord blood to improve engraftment after cord blood transplant.Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.Gene Therapy 2017: Progress and Future Directions.Biology and clinical application of CAR T cells for B cell malignancies Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds.Driving CAR T-cells forward Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Chimeric antigen receptor T cell therapy in AML: How close are we?Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.Avidity characterization of genetically engineered T-cells with novel and established approaches.Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

P2860

Q26745411-23076A62-D5D3-4523-86B8-26EB83A1B67F Q26745600-296D6865-9B41-4C5F-A02C-EE79F5AC5957 Q26750783-EA681B1B-523B-48A7-9040-A7D894C88C97 Q26773309-8ACDD827-072F-4A06-8468-2BF0F87B3829 Q26822769-5EAAFD22-7819-45FD-9C44-968806F062E4 Q28066792-C474A2C3-964B-48C8-8D01-9205C19EEDC9 Q28067817-73559A5A-6EBF-423F-A84C-C3236DC52CE7 Q28068378-27C75F51-CF11-4F0B-A140-DBC8F3C0735B Q28080304-3B4198B8-E1F3-4A8F-84E9-9A58C4BBC0D7 Q28553650-FCD1634B-74EE-4889-B1A5-195D7E12804E Q30243968-A88DF882-E9F3-4B40-AEB9-C943708B1F86 Q30248407-BDCD3A56-28F8-4204-82DE-44C7025B58AD Q30252944-2ABBA1C5-368F-4755-9094-AAA881D1647D Q30764873-44B65345-C993-4EEF-B79C-3ED8FCFB2F34 Q33433407-886AC07F-765B-4AD7-9849-698FA5EE0FAB Q33564364-46E47362-A607-44D5-A5D1-97CCF4AC9440 Q33593865-534518C6-3925-40D8-8AE1-5754F214CA34 Q33711065-CA36E4AE-05C6-4A74-A22D-DD299B98407D Q33738328-5A567EB2-6260-47BC-99AD-D505E735AED2 Q33766995-638ACE78-4430-4B57-8382-EECDA947B829 Q33823270-E41C6F46-0872-4F89-876F-41FB83813450 Q33827997-323A36B7-7C86-4157-A8BD-C1440A69579B Q33851168-039F650A-68D7-4410-AEC1-08A972167317 Q33891559-624F46DC-D9D7-4731-800A-949913527C49 Q33907565-D3E6D085-03F9-4DA7-AC6A-4F0E4270DA62 Q34046190-BE061765-E92D-4F85-A279-F14DDE034E9B Q34046505-6389B87D-E46E-4570-87C9-48ABE54E443E Q34517676-D8B5DD35-7AC6-4116-80F1-E47D8FF842E7 Q34545962-28FA4F2D-706F-4B68-9C92-8887BA6674F9 Q34553167-6D73AFAF-0887-4D01-A1DC-B74EFAC4531A Q36076472-33F8A2DC-79E0-44B4-81FF-C6781FB06D35 Q36195192-553A9C1E-E4B9-4083-BA4B-88727A16B349 Q36474226-7558F215-F589-41B2-9B31-B162B5D0159E Q36547199-FAAAB66A-7E77-4BDC-A4FC-89329D3E7E1D Q36651344-D2E71C37-0553-4405-8EE7-AE189DAEF45F Q36777093-43ED08CD-139F-4883-AD1E-7B63C225B3CE Q36830759-856E14F3-6CD2-47D9-BEEF-99B22AF87E14 Q36951727-1C1220B7-8497-4925-AEA8-27B1D03905F2 Q36982805-28D34671-2A6B-4525-A546-93FDD920573D Q37015682-FE2CDCF2-DE79-485B-AD1E-A1B512812BFB

P2860

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q41429394

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Chimeric antigen receptor T ce ...... chronic lymphocytic leukemia.

@en

type

label

Chimeric antigen receptor T ce ...... chronic lymphocytic leukemia.

@en

prefLabel

Chimeric antigen receptor T ce ...... chronic lymphocytic leukemia.

@en

P1433

Q41429394-6A2F1877-A4E7-4564-A673-E3884D2D1AF0

P1476

Q41429394-0C1915CE-2B87-4619-A87B-13FE942AB8BC

P2093

Q41429394-0050AFB9-6E05-47A3-977C-108830C11F10

Q41429394-31D7B44B-78B3-47A5-9AD3-73F6E45F2EDA

Q41429394-328F7AFC-0A5C-4407-BA35-B6FA2D2F3687

Q41429394-40F6F2AF-BA05-4302-B1B3-A45F4B01E7DE

Q41429394-46167EA4-5120-4764-BD6B-7FFEC112BE01

Q41429394-68BB2715-9DD1-4D7B-BB76-07C69018774B

Q41429394-72E473C1-04F0-45EA-AD39-0A6F6917A220

Q41429394-76AD1D30-0A5D-40AF-96D9-2271CCB85FDF

Q41429394-93AEF841-765D-460F-B54F-C7E500E2CEB4

Q41429394-981C024C-7B36-468E-9E93-8498630DCE3D

P2860

Q41429394-03E4081B-8E7E-4EEE-B33B-935F928832EA

Q41429394-15F021B3-0800-43D5-B0F2-A1F06FE56A6D

Q41429394-20A97DF1-8444-4CE7-962C-0BBDE0A7CB65

Q41429394-253D99A0-06C2-4681-8F91-ED26C4BC77C0

Q41429394-2C97E403-11DE-461B-BB14-C9F3859B68A7

Q41429394-33D49FC1-329B-40F3-8B78-7A2C3616B51F

Q41429394-36275398-66EA-4907-97FB-284C9F9FDD01

Q41429394-40474765-F6A7-4AC8-B0CE-A276D0F0DB34

Q41429394-41F68B30-948A-449D-A324-71A428CC56C4

Q41429394-43785E5D-56D8-407F-B887-01C24D5B4306

P304

Q41429394-DC6C5FCF-A3F9-4DE5-96CA-B4D898CE1668

P31

Q41429394-B3DCD444-821C-4765-9A32-C2FB77A40E36

P356

Q41429394-A98244CD-D8A6-4283-9F41-7F062C03FDE6

P407

Q41429394-863F8856-78FF-4D4E-848C-2EA592536C6C

P433

Q41429394-6A1050B3-23E3-4E01-86A0-1887C9A20272

P478

Q41429394-9FAB5A75-715D-4C3F-B600-1121FE381A7A

P577

Q41429394-7267FCDC-EAB3-489A-BC11-059B715264FA

P698

Q41429394-90C948DA-B3C7-4EDE-BB0D-BC03C427D52E

P921

Q41429394-54DCA798-3D47-4EAF-AF45-272B3118EDC2

Q41429394-95027C46-08CD-469A-BAF5-F3F2A12C28A5

P932

Q41429394-64BDF30E-DABD-4002-A126-196399CD6F1E

P356

SCITRANSLMED.AAC5415

P1433

Science Translational Medicine

P1476

Chimeric antigen receptor T ce ...... chronic lymphocytic leukemia.

@en

P2093

Adam Bagg

http://www.w3.org/2001/XMLSchema#string

Alison W Loren

http://www.w3.org/2001/XMLSchema#string

Angela Shen

http://www.w3.org/2001/XMLSchema#string

Anne Chew

http://www.w3.org/2001/XMLSchema#string

Bruce L Levine

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

David Ambrose

http://www.w3.org/2001/XMLSchema#string

David L Porter

http://www.w3.org/2001/XMLSchema#string

Jan J Melenhorst

http://www.w3.org/2001/XMLSchema#string

Katherine T Marcucci

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Gene transfer in humans using a conditionally replicating lentiviral vector

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

Current concepts in the diagnosis and management of cytokine release syndrome.

P304

303ra139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAC5415

http://www.w3.org/2001/XMLSchema#string

P407

P433

303

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26333935

http://www.w3.org/2001/XMLSchema#string

P921

P932

5909068

http://www.w3.org/2001/XMLSchema#string